The knockdown of OPN expression induces cell death in AML blasts, CD34+/CD38-/CD123+ leukemic stem and also progenitor cells (LSPCs).13 Higher levels of marrow OPN in AML patients implies the prognostic factor role for OPN compared to normal control patients.14 The prominent efforts for therapy in AML are being directed toward identifying therapeutic targets to eradicate quiescent leukemia-initiating cells (LICs) without any impact on normal hematopoiesis. The gene discussed is SPP1; the disease is acute myeloid leukemia.